Clinically validated
15,000+ interventions performed to date with no reported side effects.
INNOVATIVE AIRWAY SOLUTIONS
Transforming pulmonary care.
A scalable medical technology platform addressing over 600 million patients worldwide. The Resector Balloon is reshaping how airway disease is treated — across every hospital, every geography.
THE PROBLEM
Pulmonary disease is a global crisis — and current care cannot keep up.
More than 600 million patients live with COPD worldwide, and lung cancer adds another 2.5 million new cases every year. Treatment options remain limited, invasive, or unaffordable for the majority of those who need them.
COPD is projected to cost developed countries over $2 trillion by 2030, with per-patient costs reaching $4,800 a year. Hospitalization alone often exceeds $3,500 per admission, yet innovation in interventional pulmonology has stagnated for decades.
Hospitals face a widening gap — rising demand, aging populations, and no scalable answer for the majority of airway disease presentations.
0M+
COPD patients worldwide
$0T
Projected COPD cost by 2030
0.0M
New lung cancer cases per year
THE TECHNOLOGY
Meet the Resector Balloon.
A minimally invasive platform designed to treat airway disease with precision, safety, and scalability — engineered for any hospital, any geography.
Airway anatomy. The Resector Balloon is designed to navigate the bronchial tree with precision.
Minimally invasive
Short procedure times, faster recovery, outpatient-feasible.
Globally deployable
A scalable, capital-light model built for high-volume markets and emerging healthcare systems alike.
HOW IT WORKS
Three steps to restored airflow.
01
Airway obstruction
The bronchial tree is narrowed by pathological tissue, mucus retention, or chronic inflammation — restricting airflow and oxygen exchange.
02
Bronchoscopic intervention
Under flexible bronchoscopy, the Resector Balloon is advanced into the target airway. Controlled mechanical action removes obstructive tissue without open surgery.
03
Restored airflow
The airway is reopened. Patients typically experience immediate functional improvement in breathing capacity and oxygen saturation.
BEFORE & AFTER
From obstructed to open.
ENDOBRONCHIAL VALVES
Karakoca Endobronchial Valves
A new generation of active, reusable valve therapy for emphysema
Karakoca Endobronchial Valves represent a next-generation innovation in bronchoscopic lung volume reduction (BLVR), specifically designed for patients suffering from advanced emphysema. Unlike conventional one-time-use valves, Karakoca valves are active, cleanable, and repositionable, offering a fundamentally different approach to long-term disease management.
WHAT MAKES KARAKOCA VALVES DIFFERENT
Active & reusable technology
Karakoca valves are designed to be retrieved, cleaned, and re-implanted, maintaining functionality over time. This contrasts sharply with traditional 'passive' valves that are single-use and disposable.
Cost-efficient treatment model
By enabling reuse and repositioning, Karakoca valves significantly reduce overall treatment costs, making advanced emphysema therapy more accessible for healthcare systems and patients.
Dynamic airflow control
These valves actively regulate airflow, allowing targeted lung deflation (atelectasis) while preserving healthy lung regions — improving breathing mechanics and patient quality of life.
WHICH PATIENTS BENEFIT
Indications
- Severe emphysema (COPD-related) with hyperinflation
- Heterogeneous or selected homogeneous emphysema patterns
- Patients who remain symptomatic despite optimal medical therapy
- Individuals who are not suitable candidates for lung surgery
- Evidence of target lobes suitable for volume reduction (based on CT and functional assessment)
Patient selection
Proper patient selection is essential and typically includes:
- Pulmonary function tests (PFTs)
- High-resolution CT imaging
- Assessment of collateral ventilation
HOW THE PROCEDURE WORKS
Performed via flexible or rigid bronchoscopy. No open surgery.
- 01
A bronchoscope is introduced into the airways.
- 02
The target bronchus is identified.
- 03
One or more valves are placed to block airflow into the diseased lung segment.
- 04
Trapped air exits, leading to gradual lung deflation.
- 05
Healthier lung areas expand and function more efficiently.
CLINICAL BENEFITS
- Improved breathing capacity (FEV1)
- Reduced lung hyperinflation
- Enhanced exercise tolerance
- Better quality of life
- Minimally invasive alternative to lung volume reduction surgery
A PARADIGM SHIFT IN EMPHYSEMA TREATMENT
From single-use implants to a sustainable, adaptive model.
Traditional endobronchial valves are passive, single-use implants, leading to higher cumulative costs and limited flexibility. Karakoca Endobronchial Valves introduce a sustainable, adaptive, and economically efficient model, aligning with the future of interventional pulmonology.
- Reusable technology
- Personalized treatment adjustments
- Scalable for global healthcare systems
THE MARKET
A category-defining opportunity.
The global market for interventional pulmonology exceeds hundreds of billions, driven by aging populations, rising smoking-attributable disease in emerging markets, and an enormous unmet need for outpatient-feasible airway interventions.
0M+
Addressable COPD patient pool
$0B
US direct COPD spend (2020)
$0T
Developed-world burden by 2030
0+
Interventions performed to date
Annual direct costs and total economic burden of COPD across selected OECD countries.
| Country | Cost per patient (USD) | National burden | Primary cost driver |
|---|---|---|---|
| USA | ~$9,981 – $10,367 | ~$49 B | Hospitalizations & ER visits |
| Germany | ~$8,644 | ~€15 – 20 B | Long-term care & rehabilitation |
| France | ~$5,200 – $6,000 | ~€10 – 12 B | Medication & specialist visits |
| UK | ~$2,100 – $4,500 | ~£1.9 B (direct) | Emergency admissions |
| Türkiye | ~$1,031 – $1,500 | ~$2.5 – 3 B | Hospitalization & exacerbations |
GLOBAL INFRASTRUCTURE
Two hubs. One global platform.
BronchoTech operates through a deliberately structured dual-hub model, giving direct access to two of the world's most strategically important medtech corridors.
Shanghai
Positioned for volume and rapid scalability across China and the broader Asian market. Our engine for clinical throughput, manufacturing proximity, and physician training at scale.
4.7B
Population reach
2027
Launch
Istanbul
A gateway into European and Middle Eastern healthcare systems. Drives medical tourism access, regulatory pathways into developed markets, and regional partnerships.
2.1B
Population reach
2027
Launch
TRAINING THE NEXT GENERATION
A global movement, not just a device.
BronchoTech is more than a technology — it's a global mission to equip the next generation of interventional pulmonologists with the skills to scale precision airway therapy. Train-the-Trainer programs, certified workshops, and regional centers of excellence are building the worldwide network that will deliver this standard of care.
Train-the-Trainer programs
International workshops and live procedural demonstrations across Europe, Asia, and North America — taught by physicians who pioneered the technique.
Physician certification
A structured curriculum delivered through the Interventional Pulmonology Association — building proficiency from first procedures through advanced complex cases.
Regional centers of excellence
Clinical hubs that double as training infrastructure — embedding skills, protocols, and follow-up data wherever care is delivered.
0+
Physicians trained
0+
Partner countries
0
Accredited centers
CLINICAL EVIDENCE
Peer-reviewed research behind the platform.
The Resector Balloon is grounded in over a decade of published clinical work. Six peer-reviewed studies, from first-in-human reports through a 188-case follow-up series, anchor the evidence base.
Research & Evidence
The data behind the disease.
Peer-reviewed evidence on the global, regional, and economic burden of chronic respiratory disease.
Economic Burden of COPD in Europe
Reported mean annual cost per patient (€) by country and cost factor
Panel A — Cost factors by country
- Direct Cost
- Hospitalization
- Prescription
- Outpatient
- Productivity Loss
- Early Retirement
Direct Cost trendline
Panel B — Same data, transposed by cost factor
- Norway
- Denmark
- Germany
- Italy
- Sweden
- Greece
- Belgium
- Serbia
- Spain
Healthcare Costs and Mortality Trends — COPD vs Non-COPD Cohort, Singapore
Annual healthcare cost per person (SGD) and 1-year mortality, 2012–2019
COPD Patients
Non-COPD Patients
- Hospitalisations
- ED
- Primary care
- Specialist care
- 1-yr mortality
Global and Asian Burden of Chronic Respiratory Diseases, 2023
Distribution of DALYs by region, country, and disease type
Global DALY Distribution
Asia by Country
DALYs by Country and Disease Type
Geography
- Asia
- Global excluding Asia
Disease type
- COPD
- Asthma
- ILD and pulmonary sarcoidosis
- Other chronic respiratory diseases
- Pneumoconiosis
Country
- India
- China
- Bangladesh
- Indonesia
- Pakistan
- Japan
- Other Asia
PLATFORM IN PRACTICE
See the Resector Balloon in action.
Clinical footage translated from the original Turkish — an inside look at how the Resector Balloon is deployed in real interventional practice.
INTELLECTUAL PROPERTY
Patent-protected across key jurisdictions.
The Resector Balloon is registered with both the European Union Intellectual Property Office and the United States Patent and Trademark Office — securing the platform's commercial moat across the world's two largest medtech markets.
European Union Intellectual Property Office
European Union
No. 006267597-0002 · Registered 26 February 2019
US Patent and Trademark Office
United States
Granted patent
MEET THE TEAM
The team building the new global standard.
BronchoTech is led by a small group of operators, clinicians, and policymakers who have spent their careers at the intersection of pulmonary medicine, global health systems, and capital.
FOUNDER & PRESIDENT
Prof. Dr. Yalçın Karakoca, MD
Chief Medical Innovator · Pioneer in Interventional Pulmonology
A leading authority in interventional pulmonology and globally recognized innovator in advanced bronchoscopic therapies. Founder of Turkey's first Interventional Bronchoscopy Center and inventor of the Resector Balloon technology — recognized at the World Bronchology Congress in Tokyo.
CEO
Dukagjin Hysa
Healthcare Strategist · Global MedTech Builder
Visionary executive at the intersection of medical innovation and global capital. As CEO of BronchoTech, he leads the international platform transforming the treatment of pulmonary disease through disruptive interventional technologies.
FOR INVESTORS
A path to global category leadership.
Three phases. Ten years. One objective — establish BronchoTech as the global standard in interventional pulmonology, with anchor hubs in Asia and Europe and full commercial scale across developed markets.
2027 – 2029
Phase 1 — Foundation
- Launch of Shanghai and Istanbul hubs
- First commercial treatments and physician training programs
- Initial strategic partnerships across Asia and Europe
Clinical validation and early revenue
2030 – 2033
Phase 2 — Scale
- Expansion across Asia and Europe
- Full physician certification pipeline
- Standardization of procedural protocols
Platform-level recognition
2034 – 2037
Phase 3 — Global
- US market entry
- Global adoption across healthcare systems
- Full commercial scale across developed and emerging markets
Market leadership
PARTNERSHIP OPPORTUNITIES
Strategic investors
Capital partners aligned with a 10-year platform thesis and global scale ambitions.
Clinical partners
Hospitals and academic centers integrating the platform into care pathways and training.
Distribution partners
Regional distributors and health systems delivering the platform across emerging markets.
Download corporate presentation
PDF · download the full investor deck, or request more via investors@bronchotech.com
GET IN TOUCH
Partner with us on the future of pulmonary care.
Whether you are an investor, a clinical partner, a distributor, or a health system considering integration, we'd like to talk.
PRIMARY HUB · ASIA
Shanghai
PRIMARY HUB · EUROPE & MENA
Istanbul
PRIMARY HUB · ASIA
Hainan
RESECTOR BALLOON TECHNOLOGY
Redefining airway treatment in interventional pulmonology.
The Resector Balloon is an innovative bronchoscopic technology developed to address complex airway obstruction and chronic respiratory conditions, particularly COPD, chronic bronchitis, and severe asthma.
Designed as a minimally invasive therapeutic solution, the Resector Balloon enables physicians to mechanically restore airway patency by removing pathological tissue and improving airflow within the bronchial system. The procedure is performed through interventional bronchoscopy, avoiding the need for open surgery while offering immediate and measurable clinical benefits.